These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
423 related items for PubMed ID: 15643003
1. Induction of mucosal B-cell memory by intranasal immunization of mice with respiratory syncytial virus. Valosky J, Hishiki H, Zaoutis TE, Coffin SE. Clin Diagn Lab Immunol; 2005 Jan; 12(1):171-9. PubMed ID: 15643003 [Abstract] [Full Text] [Related]
2. Induction of mucosal and systemic immunity against respiratory syncytial virus by inactivated virus supplemented with TLR9 and NOD2 ligands. Shafique M, Wilschut J, de Haan A. Vaccine; 2012 Jan 11; 30(3):597-606. PubMed ID: 22120195 [Abstract] [Full Text] [Related]
3. Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology. Cyr SL, Jones T, Stoica-Popescu I, Brewer A, Chabot S, Lussier M, Burt D, Ward BJ. Vaccine; 2007 Jul 20; 25(29):5378-89. PubMed ID: 17561317 [Abstract] [Full Text] [Related]
4. Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c mice. Fu Y, He J, Zheng X, Wu Q, Zhang M, Wang X, Wang Y, Xie C, Tang Q, Wei W, Wang M, Song J, Qu J, Zhang Y, Wang X, Hong T. Biochem Biophys Res Commun; 2009 Apr 17; 381(4):528-32. PubMed ID: 19233131 [Abstract] [Full Text] [Related]
5. Intranasal immunisation with inactivated RSV and bacterial adjuvants induces mucosal protection and abrogates eosinophilia upon challenge. Etchart N, Baaten B, Andersen SR, Hyland L, Wong SY, Hou S. Eur J Immunol; 2006 May 17; 36(5):1136-44. PubMed ID: 16619288 [Abstract] [Full Text] [Related]
6. Single mucosal immunization of recombinant adenovirus-based vaccine expressing F1 protein fragment induces protective mucosal immunity against respiratory syncytial virus infection. Kim S, Jang JE, Yu JR, Chang J. Vaccine; 2010 May 14; 28(22):3801-8. PubMed ID: 20362203 [Abstract] [Full Text] [Related]
7. Murine host responses to respiratory syncytial virus (RSV) following intranasal administration of a Protollin-adjuvanted, epitope-enhanced recombinant G protein vaccine. Huang Y, Cyr SL, Burt DS, Anderson R. J Clin Virol; 2009 Apr 14; 44(4):287-91. PubMed ID: 19233722 [Abstract] [Full Text] [Related]
8. Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques. Elliott MB, Chen T, Terio NB, Chong SY, Abdullah R, Luckay A, Egan MA, Boutilier LA, Melville K, Lerch RA, Long D, Eldridge JH, Parks CL, Udem SA, Hancock GE. Vaccine; 2007 Oct 10; 25(41):7132-44. PubMed ID: 17850933 [Abstract] [Full Text] [Related]
9. Pulmonary T cells induced by respiratory syncytial virus are functional and can make an important contribution to long-lived protective immunity. Ostler T, Ehl S. Eur J Immunol; 2002 Sep 10; 32(9):2562-9. PubMed ID: 12207340 [Abstract] [Full Text] [Related]
10. Passive IgA monoclonal antibody is no more effective than IgG at protecting mice from mucosal challenge with respiratory syncytial virus. Fisher RG, Crowe JE, Johnson TR, Tang YW, Graham BS. J Infect Dis; 1999 Oct 10; 180(4):1324-7. PubMed ID: 10479165 [Abstract] [Full Text] [Related]
11. Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection. Johnson TR, Graham BS. Pediatr Infect Dis J; 2004 Jan 10; 23(1 Suppl):S46-57. PubMed ID: 14730270 [Abstract] [Full Text] [Related]
13. A single intranasal immunization with a subunit vaccine formulation induces higher mucosal IgA production than live respiratory syncytial virus. Garg R, Theaker M, Martinez EC, van Drunen Littel-van den Hurk S. Virology; 2016 Dec 10; 499():288-297. PubMed ID: 27721128 [Abstract] [Full Text] [Related]
14. C57Bl/6 mice are protected from respiratory syncytial virus (RSV) challenge and IL-5 associated pulmonary eosinophilic infiltrates following intranasal immunization with Protollin-eRSV vaccine. Cyr SL, Jones T, Stoica-Popescu I, Burt D, Ward BJ. Vaccine; 2007 Apr 20; 25(16):3228-32. PubMed ID: 17374422 [Abstract] [Full Text] [Related]
16. Response of calves to challenge exposure with virulent bovine respiratory syncytial virus following intranasal administration of vaccines formulated for parenteral administration. Ellis J, Gow S, West K, Waldner C, Rhodes C, Mutwiri G, Rosenberg H. J Am Vet Med Assoc; 2007 Jan 15; 230(2):233-43. PubMed ID: 17223757 [Abstract] [Full Text] [Related]
17. Pulmonary delivery of respiratory syncytial virus DNA vaccines using macroaggregated albumin particles. Harcourt JL, Anderson LJ, Sullender W, Tripp RA. Vaccine; 2004 Jun 02; 22(17-18):2248-60. PubMed ID: 15149784 [Abstract] [Full Text] [Related]
19. Long-lasting balanced immunity and protective efficacy against respiratory syncytial virus in mice induced by a recombinant protein G1F/M2. Zeng R, Qi X, Gong W, Mei X, Wei L, Ma C, Yin X. Vaccine; 2007 Oct 16; 25(42):7422-8. PubMed ID: 17850930 [Abstract] [Full Text] [Related]
20. Respiratory syncytial virus (RSV)-induced airway hyperresponsiveness in allergically sensitized mice is inhibited by live RSV and exacerbated by formalin-inactivated RSV. Peebles RS, Sheller JR, Collins RD, Jarzecka K, Mitchell DB, Graham BS. J Infect Dis; 2000 Sep 16; 182(3):671-7. PubMed ID: 10950758 [Abstract] [Full Text] [Related] Page: [Next] [New Search]